...
首页> 外文期刊>The Lancet >Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial.
【24h】

Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial.

机译:远程监控和自我管理控制高血压(TASMINH2):一项随机对照试验。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Control of blood pressure is a key component of cardiovascular disease prevention, but is difficult to achieve and until recently has been the sole preserve of health professionals. This study assessed whether self-management by people with poorly controlled hypertension resulted in better blood pressure control compared with usual care. METHODS: This randomised controlled trial was undertaken in 24 general practices in the UK. Patients aged 35-85 years were eligible for enrolment if they had blood pressure more than 140/90 mm Hg despite antihypertensive treatment and were willing to self-manage their hypertension. Participants were randomly assigned in a 1:1 ratio to self-management, consisting of self-monitoring of blood pressure and self-titration of antihypertensive drugs, combined with telemonitoring of home blood pressure measurements or to usual care. Randomisation was done by use of a central web-based system and was stratified by general practice with minimisation for sex, baseline systolic blood pressure, and presence or absence of diabetes or chronic kidney disease. Neither participants nor investigators were masked to group assignment. The primary endpoint was change in mean systolic blood pressure between baseline and each follow-up point (6 months and 12 months). All randomised patients who attended follow-up visits at 6 months and 12 months and had complete data for the primary outcome were included in the analysis, without imputation for missing data. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN17585681. FINDINGS: 527 participants were randomly assigned to self-management (n=263) or control (n=264), of whom 480 (91%; self-management, n=234; control, n=246) were included in the primary analysis. Mean systolic blood pressure decreased by 12.9 mm Hg (95% CI 10.4-15.5) from baseline to 6 months in the self-management group and by 9.2 mm Hg (6.7-11.8) in the control group (difference between groups 3.7 mm Hg, 0.8-6.6; p=0.013). From baseline to 12 months, systolic blood pressure decreased by 17.6 mm Hg (14.9-20.3) in the self-management group and by 12.2 mm Hg (9.5-14.9) in the control group (difference between groups 5.4 mm Hg, 2.4-8.5; p=0.0004). Frequency of most side-effects did not differ between groups, apart from leg swelling (self-management, 74 patients [32%]; control, 55 patients [22%]; p=0.022). INTERPRETATION: Self-management of hypertension in combination with telemonitoring of blood pressure measurements represents an important new addition to control of hypertension in primary care. FUNDING: Department of Health Policy Research Programme, National Coordinating Centre for Research Capacity Development, and Midlands Research Practices Consortium.
机译:背景:控制血压是预防心血管疾病的关键组成部分,但很难实现,直到最近一直是卫生专业人员的唯一选择。这项研究评估了血压控制不佳的人的自我管理与常规护理相比是否能更好地控制血压。方法:该随机对照试验在英国的24种常规实践中进行。如果年龄在35-85岁之间,尽管进行了降压治疗,但血压仍超过140/90 mm Hg,并且愿意自行管理高血压,则符合入组条件。参与者按照1:1的比例进行自我管理,包括血压自我监测和降压药自我滴定,家庭血压测量的远程监测或常规护理。随机分组是通过使用基于中央网络的系统进行的,并且通过常规做法进行了分层,并尽量减少了性别,基线收缩压以及是否存在糖尿病或慢性肾脏病。参与者和调查人员都没有被掩盖到小组任务中。主要终点是基线与每个随访点(6个月和12个月)之间的平均收缩压变化。分析中包括所有在6个月和12个月时接受随访并具有完整的主要结局数据的随机患者,但没有对缺失的数据进行估算。该研究已注册为国际标准随机对照试验,编号为ISRCTN17585681。结果:527名参与者被随机分配到自我管理(n = 263)或对照组(n = 264),其中480名(91%;自我管理,n = 234;对照组,n = 246)被包括在小学分析。自我管理组的平均收缩压从基线水平下降12.9 mm Hg(95%CI 10.4-15.5)至6个月,而对照组的平均收缩压下降9.2 mm Hg(6.7-11.8)(组间3.7 mm Hg, 0.8-6.6; p = 0.013)。从基线到12个月,自我管理组的收缩压降低了17.6 mm Hg(14.9-20.3),而对照组的收缩压降低了12.2 mm Hg(9.5-14.9)(组之间的差异为5.4 mm Hg,2.4-8.5) ; p = 0.0004)。除腿部肿胀外,各组之间大多数副作用的发生率无差异(自我管理,74例[32%];对照,55例[22%]; p = 0.022)。解释:高血压的自我管理与血压测量的远程监测相结合,是控制初级保健中高血压的重要新手段。资金:卫生政策研究计划部,国家研究能力开发协调中心和中部地区研究实践财团。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号